Amplifica Closes $26M Series B for Hair Growth Injectables

Fundraise Insider tracks newly funded startups each week and delivers verified sales leads of C-suite contacts straight to your inbox, so you reach the right people while the funding is still fresh. See pricing.

Amplifica Holdings Group closed an oversubscribed $26 million Series B preferred stock financing on August 12, 2026. Tasso Partners led the round, with Eli Lilly and Company, principals of Scopia Capital Management and a mix of new and existing investors joining.

The San Diego company is a clinical stage biopharmaceutical business working on hair growth, and its approach is different from the topical and oral products that dominate the category. Amplifica has assembled a proprietary portfolio of signaling molecules that govern the hair follicle growth cycle, with candidates designed to wake dormant follicles and prompt new hair to grow.

The pipeline is injectable, which puts it in a different regulatory and commercial lane from consumer hair loss products.

Proceeds go toward clinical development of those candidates. Total disclosed funding for the company now sits at roughly $37.8 million, following an $11.8 million Series A in October 2022, which makes this round more than double everything raised before it.

Eli Lilly’s participation is the detail worth watching, since strategic pharmaceutical money in a California clinical stage company usually signals interest that extends past the cheque.

Suppliers and service firms selling into clinical stage drug developers can reach verified contacts at newly funded companies through Life Science Lead Generation.